
Foghorn Therapeutics FHTX
$ 5.87
13.76%
Quarterly report 2025-Q3
added 11-05-2025
Foghorn Therapeutics P/E Ratio 2011-2026 | FHTX
Annual P/E Ratio Foghorn Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.88 | -2.96 | -2.01 | -8.39 | -3.21 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.01 | -8.39 | -3.89 |
P/E Ratio of other stocks in the Biotechnology industry
| Issuer | P/E Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-0.612 | - | 2.43 % | $ 254 M | ||
|
Adagene
ADAG
|
-2.63 | $ 1.7 | 11.11 % | $ 95.7 M | ||
|
AstraZeneca PLC
AZN
|
706 | $ 95.05 | 0.42 % | $ 96.9 B | ||
|
Autolus Therapeutics plc
AUTL
|
-1.92 | $ 1.6 | -11.64 % | $ 408 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-66.5 | $ 3.53 | 0.14 % | $ 8.49 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
55.7 | - | - | $ 40.3 B | ||
|
AgeX Therapeutics
AGE
|
-0.00095 | - | -10.17 % | $ 12.2 K | ||
|
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M | ||
|
Akero Therapeutics
AKRO
|
-12.9 | - | - | $ 3.67 B | ||
|
Biogen
BIIB
|
11.9 | $ 183.04 | -2.44 % | $ 26.7 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.57 | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
-14.5 | - | -18.52 % | $ 27.3 M | ||
|
BioNTech SE
BNTX
|
6.11 | $ 100.16 | 0.31 % | $ 27.2 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-400 | $ 4.1 | -0.97 % | $ 8.92 B | ||
|
Институт стволовых клеток человека
ISKJ
|
38.8 | - | - | - | ||
|
Ascendis Pharma A/S
ASND
|
-19.2 | $ 205.63 | 1.3 % | $ 5 B | ||
|
Corcept Therapeutics Incorporated
CORT
|
46.4 | $ 37.6 | 0.25 % | $ 3.88 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
14.9 | $ 22.6 | -0.53 % | $ 2.68 B | ||
|
ARCA biopharma
ABIO
|
-5.78 | - | 1052.0 % | $ 415 M | ||
|
Acasti Pharma
ACST
|
-4.26 | - | 4.01 % | $ 150 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
-9.06 | $ 55.0 | 3.28 % | $ 4.44 B | ||
|
CRISPR Therapeutics AG
CRSP
|
-9.12 | $ 54.77 | 1.73 % | $ 4.62 B | ||
|
Catalyst Biosciences
CBIO
|
-0.393 | $ 10.78 | -0.14 % | $ 710 M | ||
|
Cytokinetics, Incorporated
CYTK
|
-0.00898 | $ 60.85 | -2.66 % | $ 6.81 M | ||
|
DBV Technologies S.A.
DBVT
|
-5.53 | $ 17.69 | 4.0 % | $ 1.72 B | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-18 | - | -15.15 % | $ 60.3 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-3.48 | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
-1.33 | - | 1.93 % | $ 17.4 M | ||
|
Albireo Pharma
ALBO
|
-15.8 | - | -0.23 % | $ 916 M | ||
|
CureVac N.V.
CVAC
|
-8.58 | - | - | $ 867 M | ||
|
Acer Therapeutics
ACER
|
-0.463 | - | 2.71 % | $ 14 M | ||
|
Celldex Therapeutics
CLDX
|
-0.00833 | $ 25.84 | -5.62 % | $ 1.66 M | ||
|
Alpine Immune Sciences
ALPN
|
-4.65 | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
-0.833 | - | 4.14 % | $ 49.1 M | ||
|
Cellectis S.A.
CLLS
|
-1.62 | $ 4.2 | -4.76 % | $ 116 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-0.203 | - | - | $ 7.46 M | ||
|
Enanta Pharmaceuticals
ENTA
|
-0.00316 | $ 12.63 | -3.66 % | $ 269 K | ||
|
Ampio Pharmaceuticals
AMPE
|
-0.077 | - | -11.43 % | $ 502 K | ||
|
Amphastar Pharmaceuticals
AMPH
|
8.2 | $ 29.04 | 4.69 % | $ 1.41 B | ||
|
Evogene Ltd.
EVGN
|
-2.18 | $ 1.1 | -1.0 % | $ 27.9 M | ||
|
Acorda Therapeutics
ACOR
|
-0.0662 | - | -24.86 % | $ 820 K | ||
|
Applied Molecular Transport
AMTI
|
-0.175 | - | - | $ 10.1 M | ||
|
Brickell Biotech
BBI
|
-2 | - | -5.38 % | $ 6.06 M | ||
|
Burford Capital Limited
BUR
|
12.2 | $ 9.59 | 1.43 % | $ 1.55 B | ||
|
Aravive
ARAV
|
-0.791 | - | -13.39 % | $ 1.45 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
-3.83 K | $ 63.42 | -1.77 % | $ 8.48 B | ||
|
Arena Pharmaceuticals
ARNA
|
-9.16 | - | -6.81 % | $ 3.04 B | ||
|
Athersys
ATHX
|
-4.62 | - | 3.77 % | $ 22.4 M | ||
|
Amicus Therapeutics
FOLD
|
-51.9 | $ 14.29 | 0.04 % | $ 4.35 B |